Literature DB >> 17368046

A biologically active angiogenesis inhibitor, human serum albumin-TIMP-2 fusion protein, secreted from Saccharomyces cerevisiae.

Woo Kyu Kang1, Eun-Kyu Park, Hee Suk Lee, Byung-Young Park, Jae-Young Chang, Min-Young Kim, Hyun Ah Kang, Jeong-Yoon Kim.   

Abstract

Tissue inhibitor of metalloproteinase-2 (TIMP-2) is an endogenous and bi-functional inhibitor of angiogenesis. TIMP-2 is expressed in an insoluble form in Escherichia coli and secreted at a very low level from yeast. Here, we report on a high level of secretion of TIMP-2 fused with human serum albumin (HSA) from the yeast Saccharomyces cerevisiae. The secreted HSA-TIMP-2 fusion protein (87kDa) was purified to greater than 95% homogeneity. The HSA-TIMP-2 protein inhibited approximately 81% of tube formation of human umbilical vein endothelial cells (HUVECs) when studied at a concentration of 187microM. The systemic administration of HSA-TIMP-2 at 40mg/kg to the C57B1/6 mouse inhibited the growth of B16BL6 tumors. Furthermore, a combination treatment of HSA-TIMP-2 with 5-fluorouracil (50mg/kg) showed significant effects on tumor growth in this model. The high level of secretion of the biologically active angiogenesis inhibitor from S. cerevisiae should facilitate fundamental research and application studies of HSA-TIMP-2, as an attractive candidate for therapeutic agents treating angiogenesis-related diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17368046     DOI: 10.1016/j.pep.2007.02.001

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  5 in total

1.  Sweeping away protein aggregation with entropic bristles: intrinsically disordered protein fusions enhance soluble expression.

Authors:  Aaron A Santner; Carrie H Croy; Farha H Vasanwala; Vladimir N Uversky; Ya-Yue J Van; A Keith Dunker
Journal:  Biochemistry       Date:  2012-09-05       Impact factor: 3.162

Review 2.  Matrix metalloproteinases as breast cancer drivers and therapeutic targets.

Authors:  Evette S Radisky; Derek C Radisky
Journal:  Front Biosci (Landmark Ed)       Date:  2015-06-01

3.  TIMP-2 fusion protein with human serum albumin potentiates anti-angiogenesis-mediated inhibition of tumor growth by suppressing MMP-2 expression.

Authors:  Mi-Sook Lee; Jae-In Jung; Seung-Hae Kwon; Sang-Mok Lee; Kyoji Morita; Song Her
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

4.  A novel fusion partner for enhanced secretion of recombinant proteins in Saccharomyces cerevisiae.

Authors:  Jung-Hoon Bae; Bong Hyun Sung; Jeong-Woo Seo; Chul Ho Kim; Jung-Hoon Sohn
Journal:  Appl Microbiol Biotechnol       Date:  2016-07-13       Impact factor: 4.813

Review 5.  Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer.

Authors:  Evette S Radisky; Maryam Raeeszadeh-Sarmazdeh; Derek C Radisky
Journal:  J Cell Biochem       Date:  2017-07-17       Impact factor: 4.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.